Oramed Issues Letter to Shareholders
Oramed Issues Letter to Shareholders USA - English Share this article Share this article - Clinical Advancements in NASH & Leptin - Discussions with Potential Partners Under Way - To view a video message from the CEO, click here NEW YORK, Jan. 27, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery technology, is pleased to provide the following Letter to Sharehold...
Source: prnewswire.com